company background image
ANGN

Angion BiomedicaNasdaqGS:ANGN Stock Report

Last Price

US$2.21

Market Cap

US$66.2m

7D

-9.8%

1Y

n/a

Updated

21 Jan, 2022

Data

Company Financials +
ANGN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANGN Stock Overview

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Angion Biomedica
Historical stock prices
Current Share PriceUS$2.21
52 Week HighUS$26.30
52 Week LowUS$2.15
Beta0
1 Month Change-18.15%
3 Month Change-74.21%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-87.02%

Recent News & Updates

Shareholder Returns

ANGNUS PharmaceuticalsUS Market
7D-9.8%-2.2%-4.0%
1Yn/a7.1%6.6%

Return vs Industry: Insufficient data to determine how ANGN performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ANGN performed against the US Market.

Price Volatility

Is ANGN's price volatile compared to industry and market?
ANGN volatility
ANGN Average Weekly Movement20.6%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: ANGN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: ANGN's weekly volatility has increased from 15% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199872Jay Venkatesanhttps://www.angion.com

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company’s lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases.

Angion Biomedica Fundamentals Summary

How do Angion Biomedica's earnings and revenue compare to its market cap?
ANGN fundamental statistics
Market CapUS$66.20m
Earnings (TTM)-US$98.34m
Revenue (TTM)US$2.83m

23.4x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANGN income statement (TTM)
RevenueUS$2.83m
Cost of RevenueUS$49.74m
Gross Profit-US$46.91m
ExpensesUS$51.43m
Earnings-US$98.34m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.28
Gross Margin-1,657.49%
Net Profit Margin-3,474.84%
Debt/Equity Ratio0%

How did ANGN perform over the long term?

See historical performance and comparison

Valuation

Is Angion Biomedica undervalued compared to its fair value and its price relative to the market?

1.03x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ANGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ANGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ANGN is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: ANGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ANGN is good value based on its PB Ratio (1x) compared to the US Pharmaceuticals industry average (2.2x).


Future Growth

How is Angion Biomedica forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

55.7%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ANGN's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if ANGN's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ANGN's revenue (55.7% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: ANGN's revenue (55.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ANGN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Angion Biomedica performed over the past 5 years?

-46.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ANGN is currently unprofitable.

Growing Profit Margin: ANGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ANGN's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ANGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: ANGN has a negative Return on Equity (-152.43%), as it is currently unprofitable.


Financial Health

How is Angion Biomedica's financial position?


Financial Position Analysis

Short Term Liabilities: ANGN's short term assets ($104.4M) exceed its short term liabilities ($17.9M).

Long Term Liabilities: ANGN's short term assets ($104.4M) exceed its long term liabilities ($27.5M).


Debt to Equity History and Analysis

Debt Level: ANGN is debt free.

Reducing Debt: ANGN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANGN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ANGN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 16.9% each year.


Dividend

What is Angion Biomedica current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ANGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Jay Venkatesan (49 yo)

3.67yrs

Tenure

US$553,228

Compensation

Dr. Jay R. Venkatesan, Ph D., M.D. MBA., is President at Angion Biomedica Corp. since January 2019 and has been its Chief Executive Officer & Director since May 2018. Dr. Venkatesan has been a Non-Employee...


CEO Compensation Analysis

Compensation vs Market: Jay's total compensation ($USD553.23K) is about average for companies of similar size in the US market ($USD582.48K).

Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ANGN's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: ANGN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ANGN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: ANGN only recently listed within the past 12 months.


Top Shareholders

Company Information

Angion Biomedica Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: Angion Biomedica Corp.
  • Ticker: ANGN
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$66.204m
  • Shares outstanding: 29.96m
  • Website: https://www.angion.com

Number of Employees


Location

  • Angion Biomedica Corp.
  • 51 Charles Lindbergh Boulevard
  • Uniondale
  • New York
  • 11553
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 00:09
End of Day Share Price2022/01/20 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.